Despite the modest sample size, we observed signficantly higher pCR rates in patients with BRCAmut cancers, but not BRCA1meth cancers, than in those with either BRCA1 and BRCA2 proficient cancers (P = 0.033, Fig. 1E). This evidence concerns the gene BRCA2 and cancer.